Watching PAVmed Inc. (PAVM) For Insider Activity

PAVmed Inc. (NASDAQ:PAVM) trading with an addition of $0.45 to $8.59 on Thursday, an upside of 5.47 percent. An average of 1,514,231 shares of common stock have been traded in the last five days. There was a gain of $0.08 in the past week. The last 20 days have seen an average of 1,956,333 shares traded, while the 50-day average volume stands at 1,985,263.

PAVM stock has decreased by -0.73% in the last month. The company shares reached their 1-month lowest point of $7.32 on 09/20/21. With the stock rallying to its 52-week high on 09/23/21, shares of the company touched a low of $1.63 and a high of $9.70 in 52 weeks. In spite of this, the price is down -11.49% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Insider Transactions

316 days have passed since PAVmed Inc. (PAVM) last reported insider trading activity. SIROVICH MATTHEW, who is 10% Owner, most recently acquired $33,203 shares at $1.96 per share on Nov 25. In this transaction, the insider spent $65,048. 10% Owner, SIROVICH MATTHEW, disposed of 53,036 shares at a price of $2.00 on Nov 24. The insider now owns more than $105,876 worth of shares. Prior to that, 10% Owner SIROVICH MATTHEW went on to Sale 75,211 shares at $1.83 each on Nov 19. An amount of $137,418 was transacted.

Valuation Metrics

PAVmed Inc. (PAVM) has a trailing price-to-earnings (P/E) ratio of 26.30 for the broader industry and 32.26 for the sector. This means investors are optimistic about the stock’s future prospects. The stock’s beta is 0.23. Other valuation ratios to consider include the price-to-book (PB) ratio at 16.61.

The quick ratio of PAVmed Inc. for the three months ended June 29 was 8.70, and the current ratio was 8.70, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $53000.0 compared to revenue of $23.35 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, PAVmed Inc.’s return on assets was -109.80%, compared to -441.8% over the last five years. For the broader industry, ROE averaged 3.96 over the past year.

Earnings Surprise

The analyst consensus anticipated PAVmed Inc.’s latest quarter earnings to come in at -$0.1 per share, but it turned out to be -$0.14, a -40.00% surprise. For the quarter, EBITDA amounted to -$12.95 million. At the end of the quarter ending June 29, PAVmed Inc.’s stock balance sheet showed total liabilities of 5.33 million. Shareholders own equity worth $84.77 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at PAVmed Inc. (PAVM) price momentum. RSI 9-day as of the close on 06 October was 56.68%, suggesting the stock is Neutral, with historical volatility in this time frame at 60.75%.

As of today, PAVM’s price is $8.26 +0.94% or $0.08 from its 5-day moving average. PAVM is currently trading +3.11% higher than its 20-day SMA and +118.23% higher than its 100-day SMA. However, the stock’s current price level is +25.84% above the SMA50 and +387.01% above the SMA200.

The stochastic %K and %D were 43.84% and 38.14%, respectively, and the average true range (ATR) was 0.54. With the 14-day stochastic at 54.62% and the average true range at 0.53, the RSI (14) stands at 56.53%. The stock has reached -0.02 on the 9-day MACD Oscillator while the 14-day reading was at -0.05.

Analyst Ratings

Cantor Fitzgerald launched coverage on PAVmed Inc. (NASDAQ: PAVM) in its analyst report released on March 30, 2021. The firm assigned the stock a an Overweight rating.The consensus rating for PAVmed Inc. (PAVM) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell PAVM, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.

What is PAVM’s price target for the next 12 months?

Analysts predict a range of price targets between $8.00 and $12.00, with a median target of $9.00. Taking a look at these predictions, the average price target given by analysts for PAVmed Inc. (PAVM) stock is $9.50.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam